{
    "organizations": [],
    "uuid": "4e71c0aaea2b638672217824f5b6aa048ab10748",
    "author": "",
    "url": "https://www.reuters.com/article/brief-asterias-biotherapeutics-reports-m/brief-asterias-biotherapeutics-reports-milestone-targets-for-2018-idUSFWN1OZ0N0",
    "ord_in_thread": 0,
    "title": "BRIEF-Asterias Biotherapeutics Reports Milestone Targets For 2018",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "January 4, 2018 / 5:42 PM / in 8 minutes BRIEF-Asterias Biotherapeutics Reports Milestone Targets For 2018 Reuters Staff 1 Min Read \nJan 4 (Reuters) - Asterias Biotherapeutics Inc: \n* ASTERIAS BIOTHERAPEUTICS INC - AS OF DECEMBER 31, 2017, ASTERIASâ€™ CASH AND CASH EQUIVALENTS TOTALED APPROXIMATELY $21.6 MILLION \n* ASTERIAS BIOTHERAPEUTICS SAYS INTENDS TO CONTINUE DISCUSSIONS WITH FDA TO ACHIEVE CLEARANCE ON DESIGN OF NEXT STUDY FOR AST-OPC1 \n* ASTERIAS BIOTHERAPEUTICS SAYS HAS SUFFICIENT RESOURCES TO FUND OPERATIONS THROUGH MID-2019 Source text for Eikon: Further company coverage:",
    "published": "2018-01-04T19:42:00.000+02:00",
    "crawled": "2018-01-04T20:06:43.020+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "january",
        "pm",
        "minute",
        "biotherapeutics",
        "report",
        "milestone",
        "target",
        "reuters",
        "staff",
        "min",
        "read",
        "jan",
        "reuters",
        "asterias",
        "biotherapeutics",
        "inc",
        "asterias",
        "biotherapeutics",
        "inc",
        "december",
        "asterias",
        "cash",
        "cash",
        "equivalent",
        "totaled",
        "approximately",
        "million",
        "asterias",
        "biotherapeutics",
        "say",
        "intends",
        "continue",
        "discussion",
        "fda",
        "achieve",
        "clearance",
        "design",
        "next",
        "study",
        "asterias",
        "biotherapeutics",
        "say",
        "sufficient",
        "resource",
        "fund",
        "operation",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}